Abstract
Anti-TNFα therapy for rheumatic diseases appears to be safe in patients with chronic hepatitis C. However, the administration of anti-TNFα agents without initiation of prophylactic antiviral therapy (lamivudine 100 mg/day) in patients with chronic HBV infection results in exacerbation of liver disease. In this report, we describe our experience of long-term anti-TNFα therapy for ankylosing spondylitis in two inactive HBsAg carriers without preemptive antiviral treatment.
This is a preview of subscription content, log in via an institution to check access.
References
Calabrese LH, Zein N, Vassilopoulos D (2004) Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Ann Rheum Dis 63(Suppl 2):ii18–ii24
Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Bijlsma JW et al (2005) Updated consensus statement on biological agents, specifically tumour necrosis factor α (TNFα) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. Ann Rheum Dis 64(Suppl 4):iv2–iv14
Guidotti LG, Ishikawa T, Hobbs MV, Matzke B, Schreiber R, Chisari FV (1996) Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 4:25–36
Ostuni P, Botsios C, Punzi L, Sfriso P, Todesco S (2003) Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis 62:686–687
Oniankitan O, Duvoux C, Challine D, Mallat A, Chevalier X, Pawlotsky JM et al (2004) Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C. J Rheumatol 31:107–109
Wendling D, Auge B, Bettinger D, Lohse A, Le Huede G, Bresson-Hadni S et al (2005) Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy. Ann Rheum Dis 64:788–789
Roux CH, Brocq O, Breuil V, Albert C, Euller-Ziegler L (2006) Safety of anti-TNFα therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis. Rheumatology (Oxford) (in press)
Esteve M, Saro C, Gonzalez-Huix F, Suarez F, Forne M, Viver JM (2004) Chronic hepatitis B reactivation following infliximab therapy in Crohn’s disease patients: need for primary prophylaxis. Gut 53:1363–1365
Ueno Y, Tanaka S, Shimamoto M, Miyanaka Y, Hiyama T, Ito M et al (2005) Infliximab therapy for Crohn’s disease in a patient with chronic hepatitis. B Dig Dis Sci 50:163–166
del Valle Garcia-Sanchez M, Gomez-Camacho F, Poyato-Gonzalez A, Iglesias-Flores EM, de Dios-Vega JF, Sancho-Zapatero R (2004) Infliximab therapy in a patient with Crohn’s disease and chronic hepatitis B virus infection. Inflamm Bowel Dis 10:701–702
Millonig G, Kern M, Ludwiczek O, Nachbaur K, Vogel W (2006) Subfulmitant hepatitis B after infliximab in Crohn’s disease: need for HBV-screening? World J Gastroenterol 12:974–976
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sakellariou, G.T., Chatzigiannis, I. Long-term anti-TNFα therapy for ankylosing spondylitis in two patients with chronic HBV infection. Clin Rheumatol 26, 950–952 (2007). https://doi.org/10.1007/s10067-006-0392-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-006-0392-1